Completed PHASE1 INTERVENTIONAL 2-arm NCT01223924

Single-dose Escalation Trial of M2ES in Healthy Volunteer

Randomized ，Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer

Sponsor: Protgen Ltd

Conditions Cancer

Updated 5 times since 2017 Last updated: Oct 18, 2010 Started: May 31, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01223924, this PHASE1 trial focuses on Cancer and remains completed. Sponsored by Protgen Ltd, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Protgen Ltd

Data source: Protgen Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.